Lejárt szabadalmi védettségű, tételes hatóanyagok
Hungary · Budapest · how to bid here →
Your path to submission
- Deadline: 2 November at 11:00 — 29 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: HUN, HUN, HUN, HUN.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 2 months (87 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Clear Pharma Zrt..n = 87
- 30% of the bids received came from small and medium-sized enterprises (88 procedures with a bid mix). Sector: 81%.n = 88
- The median procedure drew just one bid (171 procedures with a bid count); 61% ended with a single bidder. Sector: median 4 bids.n = 171
- 39% of this buyer's awards went to companies that had already won here before (173 awards since 2017, spread over 21 companies). 61% went to new names.n = 173 awards since 2017
- 0% of the bids received came from other countries (88 procedures with a bid mix) — all bidders, not just the winners. Sector: 5%.n = 88
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Hungary · Medical equipment & pharma, 15 contracts went to foreign companies over the last 3 years (of 2,957 recorded awards).
Submission language: HUN.
Typical field: median 1 (from 87 awards).
What the buyer is looking for
Acquisition of specific active substances protected by expired patents for the purpose of concluding a framework agreement, in Sections 1-3 of the Public Procurement Act. Section 105(1)(a) and, in the case of Part 4, the Public Procurement Act. In the framework of the open procedure referred to in Section 105(2)(a), with the possibility of extending the active period of the Framework Agreement. The subject-matter of this procurement procedure (in parts): Part 1: Infliximab IV (OENO: 06053) Basic quantity: 16 400 000 mg Optional quantity: 8 200 000 mg Part 2: Pomalidomide (OENO: 06082) Basic quantity: 201 600 mg Optional quantity: 100 800 mg Part 3: Bevacizumab (OENO: 06036) Basic quantity: 60 000 000 mg Optional quantity: 30 000 000 mg Part 4: Tocilizumab (OENO: 06054) Basic quantity: 29 400 000 mg Optional quantity: It does not allow the contracting authority to offer 14 700 000 mg in…
Show full description
… any part. AK draws the attention of economic operators to the fact that the Public Procurement Act In the light of Section 73(1)(j), a tender which contains a higher total price than the following amounts shall be invalid in all lots: Part 1: net HUF 4.106.896.200 Part 2: HUF 300 959 366 net Part 3: Net HUF 6.825.060.000 Part 4: HUF 11.852.316.000 net. BT-113 is completed for technical reasons, AK does not want to limit the maximum number of participants. Evaluation criterion in all parts is the lowest price in 16/2012. (II.16.) 6 (1) (f) GDPR. · Infliximab iv. (OENO: 06053) Basic quantity: 16 400 000 mg Optional quantity: 8 200 000 mg Total quantitative limit: 24 600 000 mg AK allows for the possibility of multivariate (alternative) bidding according to the following rules: In each alternative tender, the tenderer may offer different products (but in full compliance with the technical specifications in all respects) and different total prices for each alternative tender. Ak points out that AT may offer up to five variants, but that more than one variant is optional (only possible). Each variant participates in the evaluation at the same time. The variants offered by one AT are also in competition with each other in the same part, so that no more than one variant offered by one AT can be ranked 1st, 2nd, 3rd or 4th in one part, but it is not excluded that a variant offered by one AT may be concluded with the same tenderer in one part on the basis of several variants of the tender according to each position. For all variants, the minimum professional requirement shall be: - in each alternative, only medicinal products with the OENO code provided for in the relevant procurement section and containing a specified active substance, which fully comply with the technical specifications, may be recommended. - AK states that the products offered in an alternative offer (offer version) may only contain medicinal products belonging to one main registration number! - AK states that the products offered in different alternative offers (offer versions) of the same Bidder may only contain medicinal products belonging to different main numbers! - in all cases, the total net price of the tender for the quantitative limit of the public procurement part concerned must be indicated on the reading sheet, per variant of the tender. AK draws attention to the fact that the name, strength, presentation and form of intake of the medicinal product (product, preparation) offered by the AT is considered a detailed offer, so it can be filled in or modified in a limited way! On the closing date for submission of tenders, the proposed medicinal product must: - must have a marketing authorisation in the public register of the NNGYK, and - must be validly listed in the PUPHA strain containing the range of medicinal products accepted by the NEAK for social security (TB) support on the closing date for submission of tenders, and - the medicinal product offered must also be validly listed in the PUPHA strain at the latest at the time of conclusion of the KM (detailed: KD). AT must indicate the wholesalers of the medicinal product on the closing date for submission of tenders
What you must prove — eligibility criteria
M.1.) Alkalmatlan az ajánlattevő, amennyiben összességében nem rendelkezik a jelen felhívás feladását megelőző három évben (36 hónapban) befejezett,de legfeljebb hat éven (72 hónapon) belül megkezdett a közbeszerzés tárgyából (azaz bármely, emberi felhasználás… ▸▾
M.1.) Alkalmatlan az ajánlattevő, amennyiben összességében nem rendelkezik a jelen felhívás feladását megelőző három évben (36 hónapban) befejezett,de legfeljebb hat éven (72 hónapon) belül megkezdett a közbeszerzés tárgyából (azaz bármely, emberi felhasználás… ▸▾
M.1.) Alkalmatlan az ajánlattevő, amennyiben összességében nem rendelkezik a jelen felhívás feladását megelőző három évben (36 hónapban) befejezett,de legfeljebb hat éven (72 hónapon) belül megkezdett a közbeszerzés tárgyából (azaz bármely, emberi felhasználás… ▸▾
M.1.) Alkalmatlan az ajánlattevő, amennyiben összességében nem rendelkezik a jelen felhívás feladását megelőző három évben (36 hónapban) befejezett,de legfeljebb hat éven (72 hónapon) belül megkezdett a közbeszerzés tárgyából (azaz bármely, emberi felhasználás… ▸▾
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| HUNGAROPHARMA Gyógyszerkereskedelmi Zártkörűen Működő Részvénytársaság | 15 | 2023–2026 |
| Atlas Pharma Gyógyszernagykereskedelmi Korlátolt Felelősségű Társaság | 14 | 2023–2026 |
| PHOENIX Pharma Gyógyszerkereskedelmi Zártkörűen Működő Részvénytársaság | 9 | 2024–2026 |
| Roche (Magyarország) Gyógyszer- és Vegyianyagkereskedelmi Kft. | 8 | 2024–2026 |
| Clear Pharma Zrt. | 5 | 2024–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.